Latest

Semaglutide

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience

·May 13, 2025·6 min read

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with participants losing an average of 20.2% of their body weight versus 13.7%. The study directly compared the two drugs at their highest doses in people with obesity but without diabetes.

Featured Neuroscience

·February 12, 2025·7 min read

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption. Researchers found that weekly injections of semaglutide decreased alcohol cravings, drinking quantity, and heavy drinking days in adults with alcohol use disorder. Participants receiving semaglutide consumed less alcohol in a controlled lab setting and reported reduced cravings compared to those receiving a placebo.

Featured Neurology Neuroscience

·October 24, 2024·4 min read

Ozempic Shows Potential in Lowering Alzheimer’s Risk

New research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.

Featured Neurology Neuroscience

·October 6, 2024·5 min read

Study Finds Wegovy Reduces COVID-19 Death Risk by One-Third

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%. The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.

Featured Neurology Neuroscience

·July 12, 2024·5 min read

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

A new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.

Featured Neuroscience Psychology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

This shows a sad man and a whiskey bottle.

Featured Neuroscience Psychology

·June 8, 2023·5 min read

Ozempic Shows Potential as Treatment for Alcohol Dependence

Semaglutide, or Ozempic, a medication used for type 2 diabetes and obesity, may also be effective in treating alcohol dependence. The drug reduced alcohol relapse drinking and overall alcohol intake in rats by more than half.